Skip to main content
New — The Peptide Dictionary: 128 terms, explained simply
New guide — NAD+ for Anti-Aging: What the Science Says
New guide — GHK-Cu: the copper peptide for your skin
Not sure where to start? — A 60-second quiz points you to the path that fits your goal
New explainer — Semaglutide: what the research says, made simple
Browse — Peptide guides, made simple
New — The Peptide Dictionary: 128 terms, explained simply
New guide — NAD+ for Anti-Aging: What the Science Says
New guide — GHK-Cu: the copper peptide for your skin
Not sure where to start? — A 60-second quiz points you to the path that fits your goal
New explainer — Semaglutide: what the research says, made simple
Browse — Peptide guides, made simple
Easy-to-follow guides
Independent reviews
Vetted providers
Free to read

Home / Peptide legality / Kentucky

Peptide legality · Kentucky · updated 2026-09-21

Are peptides legal in Kentucky?

Gray area

Kentucky has no peptide-specific ban, so peptide legality in Kentucky follows the federal compounding framework and an actively enforcing state board, making the honest verdict gray rather than plainly legal or illegal.

Legal status overview

Kentucky is a gray-zone state that regulates peptides through general compounding law and rigorous board enforcement rather than a peptide-specific statute. FDA-approved products such as Wegovy® (semaglutide) are legal by prescription, while research peptides like BPC-157 are neither FDA-approved nor authorized for compounding. Compounding in Kentucky is governed by 201 KAR 2:076 together with the federal Drug Quality and Security Act and USP chapter standards, and the Board has issued specific 2025 guidance on GLP-1 compounding. Kentucky has a notable enforcement history here, so the gray zone carries real risk. This is general information, not legal or medical advice.

Key points

  • Kentucky has no statute that names or bans peptides specifically; the Kentucky Board of Pharmacy regulates them through 201 KAR 2:076, the federal Drug Quality and Security Act, and applicable USP chapter standards. [4]
  • The Kentucky Board of Pharmacy issued dedicated 2025 GLP-1 Compounding Guidance stating that compounding semaglutide or tirzepatide in a way that fails to conform with governing law may draw enforcement by both the FDA and the Board. [3]
  • As of March 2025 the FDA ended 503A compounding of semaglutide and tirzepatide once the shortages resolved, so broad compounding of these GLP-1 drugs is no longer permitted in Kentucky. [3]
  • The FDA removed BPC-157 and eleven other peptides from the Category 2 do not compound list on April 15, 2026, but did not add them to the Category 1 authorized bulk substances list, leaving them in a regulatory gray zone. [1]
  • Removal from Category 2 does not clear a peptide for compounding; BPC-157 still lacks Category 1 status, FDA approval, and a USP monograph, so it is not eligible for 503A compounding. [2]
  • Kentucky has an enforcement track record: in 2020 Tailor Made Compounding LLC, a Kentucky compounding pharmacy, and its owner were federally charged over distribution of unapproved peptides including BPC-157. [2]
  • Wegovy® (semaglutide) and Zepbound® (tirzepatide) are FDA-approved and available by prescription in Kentucky; compounded semaglutide and compounded tirzepatide are not FDA-approved, are not a generic, and have not been evaluated by the FDA. [5]
  • Somatropin (human growth hormone) is restricted nationwide by 21 U.S.C. 333(e), which limits distribution to FDA-approved indications, so anti-aging or performance use is prohibited in Kentucky. [6]

Compound-by-compound status

BPC-157
Gray area
Not FDA-approved and no USP monograph. Removed from the FDA Category 2 do not compound list on April 15, 2026, but not added to the Category 1 authorized list. Kentucky has federally prosecuted BPC-157 distribution before, so the gray status carries real enforcement risk.
GLP-1 class (semaglutide, tirzepatide)
Restricted
Wegovy® (semaglutide), Ozempic® (semaglutide), Zepbound® (tirzepatide), and Mounjaro® (tirzepatide) are FDA-approved and available by prescription in Kentucky. Compounded semaglutide and compounded tirzepatide are not FDA-approved, are not a generic, and have not been evaluated by the FDA; the Board's 2025 guidance and the March 2025 end of FDA shortage compounding sharply limit compounding.
TB-500 (thymosin beta-4 fragment)
Gray area
Not FDA-approved and no USP monograph. Removed from Category 2 on April 15, 2026, but not authorized for compounding, so it sits in the same gray zone as BPC-157 in Kentucky.
Growth hormone / somatropin
Restricted
A prescription drug whose distribution is limited by 21 U.S.C. 333(e) to FDA-approved indications ordered by a physician. Distribution for anti-aging, bodybuilding, or general wellness is a federal crime and applies in Kentucky.

Frequently asked questions

Are peptides legal in Kentucky?

Kentucky has no law that bans peptides by name. FDA-approved peptide drugs are legal by prescription, but research peptides such as BPC-157 are neither FDA-approved nor authorized for compounding, so they sit in a gray zone that the Board enforces actively. This is general information, not legal advice.

Can a Kentucky pharmacy compound BPC-157?

Not lawfully as a bulk substance today. The FDA removed BPC-157 from Category 2 in April 2026 but did not add it to the Category 1 authorized list, and it has no USP monograph and no FDA approval. Kentucky has previously pursued federal charges over unapproved peptide distribution.

What does Kentucky's GLP-1 guidance say?

The Board's 2025 GLP-1 Compounding Guidance warns that compounding semaglutide or tirzepatide outside governing law may trigger FDA and Board enforcement, and it notes that FDA-permitted shortage compounding of these drugs ended in March 2025.

Is compounded semaglutide available in Kentucky?

Wegovy® (semaglutide) and Ozempic® (semaglutide) are FDA-approved and available by prescription. Compounded semaglutide is not FDA-approved, is not a generic, and has not been evaluated by the FDA, and broad compounding ended after the 2025 shortage resolution.

Is human growth hormone legal for anti-aging in Kentucky?

No. Federal law at 21 U.S.C. 333(e) limits somatropin distribution to FDA-approved indications, and the FDA treats writing a prescription as distribution, so anti-aging or performance use is prohibited nationwide, including Kentucky.

General information based on the sourced research above, not legal advice. For a specific situation in Kentucky, consult a licensed attorney familiar with pharmaceutical law.